Clinical trials: Glomerular Disease
Chronic Kidney Disease, Endothelial Dysfunction
Study of Protective Effects of Paricalcitol on Inner Layer of Vessels and Its Protective Effect on Inflammation
The study is about possible protective effects of paricalcitol (Zemplar) upon inflammation, blood pressure and kidney function. Kidney Inflammation occurs when white blood cells become abnormally stimulated and accumulate in the…
- Conditions
- Chronic Kidney Disease, Endothelial Dysfunction, Inflammation, Hypertension
- Trial name
- NCT00428246
- Testing
- paricalcitol
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Indiana University
Obesity and Glomerulopathy
A Prospective, Single-center, Randomized, Controlled Study of Sevelamer Carbonate in the Lipid Metabolism and Uric Acid Treatment of Obesity-Related Glomerulopathy
To observe the decreased levels of low-density lipoprotein from baseline in patients with obesity-related glomerulopathy (ORG) after 12 weeks of Sevelamer Carbonate treatment.
- Trial name
- NCT02644486
- Testing
- High dosage Sevelamer Carbonate + Irbesartan, Low dosage Sevelamer Carbonate + Irbesartan, Irbesartan
- Where
- China
- Volunteers
- 4 people
- Sponsor
- Zhi-Hong Liu, M.D.
Lupus Nephritis (LN)
Atacicept in Subjects With Active Lupus Nephritis (COMPASS)
The objective of the study is to evaluate the effect of atacicept compared to placebo on changes to renal response in adult subjects with LN.
- Trial name
- COMPASS (NCT05609812)
- Testing
- Atacicept
- Where
- 33 sites in United States, Puerto Rico and 1 more
- Sponsor
- Vera Therapeutics, Inc.
Acute Kidney Injury, Chronic Kidney Insufficiency
Comparison of Two Different External Clearance Markers - Mannitol and Iohexol for Measuring Glomerular Filtration Rate
GFR is the best parameter of the real kidney function. Measurements, however are time-consuming and have limited capacity. Patients treated in the intensive care units often have more than one organ-insufficiency and acute kidney…
- Trial name
- GFR (NCT06238310)
- Testing
- Comparison of two external marker substance for measuring glomerular filtration rate
- Where
- Sweden
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Katalin Kiss
Renal Impairment
A Study to Assess the Pharmacokinetics (Uptake of Drugs by the Body), Safety and Tolerability of AZD4831 in Participants With Severe Renal Impairment and Healthy Volunteers
This is a study to compare AZD4831 pharmacokinetic (PK) parameters between participants with severe renal impairment and matched healthy volunteers following a single dose administration.
- Trial name
- NCT04949438
- Testing
- AZD4831
- Where
- Bulgaria
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
IgA Nephropathy
A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy
The purpose of this study is to determine if BHV-1400 is effective and safe in the treatment of IgA Nephropathy. Participants will be randomized in a 2:1 ratio to receive either BHV-1400 or placebo.
- Trial name
- NCT07642050
- Testing
- BHV-1400
- Volunteers
- 420 people
- Sponsor
- Biohaven Therapeutics Ltd.
Interstitial Fibrosis, Kidney Transplant; Complications
Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation
This is a randomized, double-blind, placebo-controlled trial in de novo kidney transplant patients to determine if the addition of fingolimod (brand name Gilenya®, candidate name- FTY720) on the background of standard…
- Conditions
- Interstitial Fibrosis, Kidney Transplant; Complications, Kidney Transplant Rejection, Kidney Transplant Failure and Rejection
- Trial name
- NCT05285878
- Testing
- Fingolimod
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The Methodist Hospital Research Institute
Vascular Access Complication, Apheresis Related Complication
Vascular Access Complications for Therapeutic Apheresis in Nephrology
The aim of this study is to describe vascular access complications which are used for therapeutic apheresis in Nephrology.
- Trial name
- VACTANE (NCT05894317)
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
C3G
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
The Primary Completion Date and Study Completion Date have been updated to reflect completion of the adolescent cohort, which has been added to the protocol.
- Trial name
- APPEAR-C3G (NCT04817618)
- Testing
- iptacopan
- Where
- 88 sites in United States, Argentina and 17 more
- Volunteers
- 98 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Kidney Disease (CKD)
Urologic-nephrological Care of Chronic Kidney Disease in Saxony-Anhalt/Magdeburg.
Statement: Patients with Chronic kidney disease (CKD) with an estimated glomerular filtration rate (eGFR) under 60 ml/min using the MDRD-6 (Modification of Diet in Renal Disease) formula and/or CKD-EPI (Chronic Kidney Disease…
- Trial name
- UroCKDisS (NCT02229435)
- Where
- Germany
- Volunteers
- 1,031,336 people
- Sponsor
- University of Magdeburg